HealthEquity vs WEX
HQY and WEX side by side, both in miscellaneous business services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How HQY and WEX compare
HealthEquity is the larger company, worth 1.3 times as much as WEX ($8.5B against $6.3B).
On earnings, WEX is cheaper: it trades at 15.9× trailing earnings, against 37.0× for HealthEquity.
WEX grew revenue faster over the last twelve months (9.7% versus 7.3% for HealthEquity).
HealthEquity keeps more of each dollar of sales as profit, with a net margin of 17.4% compared with 14.0% at WEX.
HealthEquity scores higher on the StockData Score (15 against 14 for WEX), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | HQY | WEX |
|---|---|---|
| Size and price | ||
| Market cap | $8.5B | $6.3B |
| Share price | $102.47 | $184.61 |
| Change, 1 year | 8.5% | 19.8% |
| Change, 5 years | 50.2% | 18.4% |
| Beta (5Y) | 0.39 | 1.03 |
| Employees | 2,814 | 6,600 |
| StockData Score | ||
| Total score | 15 (better) | 14 |
| Valuation score | 3 | 5 (better) |
| Growth score | 3 | 4 (better) |
| Performance score | 4 | 4 |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 37.0× | 15.9× (better) |
| P/S | 6.2× | 2.2× (better) |
| P/B | 4.3× (better) | 5.5× |
| EV/EBITDA | 18.0× | 6.2× (better) |
| P/FCF | 17.4× | – |
| PEG | – | 0.68 |
| FCF yield | 5.8% (better) | −5.0% |
| Fair value | $109.86 | $307.71 |
| Margin of safety | 6.7% | 40.0% (better) |
| Growth | ||
| Revenue growth (TTM) | 7.3% | 9.7% (better) |
| Revenue growth, 5Y average | 12.4% (better) | 11.3% |
| Net income growth (TTM) | 62.2% (better) | 42.6% |
| EPS growth (TTM) | 67.9% (better) | 51.3% |
| EPS growth, 5Y average | 83.0% | – |
| Profitability | ||
| Gross margin | 71.2% (better) | 60.4% |
| Operating margin | 25.8% | 26.6% (better) |
| Net margin | 17.4% (better) | 14.0% |
| FCF margin | 35.8% (better) | −10.8% |
| Return on equity | 11.4% | 35.6% (better) |
| Return on invested capital | 9.8% | 46.4% (better) |
| Financial health | ||
| Debt / equity | 0.47 (better) | 4.62 |
| Net debt / EBITDA | 1.33 | 0.05 (better) |
| Interest coverage | 6.7× | – |
| Current ratio | 2.99 (better) | 1.03 |
| Altman Z-score | 4.92 (better) | 0.84 |
| Piotroski F-score | 9 (better) | 6 |
| Dividends and buybacks | ||
| Buyback yield | 4.8% (better) | 4.2% |
| Shareholder yield | 4.8% (better) | 4.2% |
| Ownership | ||
| Held by institutions | 109% | 116% |
| Held by insiders | 1.7% | 6.4% |
| Insider net buying, 12 months | −$4.2M (better) | −$10.1M |
| Short interest, % of float | 7.4% | 8.7% |
Go deeper
- HQY stock overview
- HQY income statement
- HQY valuation and score
- WEX stock overview
- WEX income statement
- WEX valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.